All Health Care News
Top stories summarized by our editors
9/18/2019

The Business Roundtable lowered its US economic growth forecast for the year to 2.3%, a decrease from its 2.6% estimate from last quarter. The leader of the group of CEOs from the largest US companies, including a number from the health care sector, said tension related to the trade war with China and a stalled trade agreement with Mexico and Canada were factors in the lower forecast.

Full Story:
CNBC
9/18/2019

Drugviu won $5,000 in the first AHIMA pitch competition for its population health platform designed to improve clinical trial participation opportunities for people of color, provide tailored health education resources and provide an online platform for community engagement. Runners-up included Valhalla Healthcare, Uppstroms, Smarter Health and Tapcloud.

More Summaries:
AHIMA
9/18/2019

A coalition that includes the American Medical Association, the Federation of American Hospitals and the College of Healthcare Information Management Executives asked the ONC to phase in compliance with proposed data blocking and interoperability rules, clarify some of the language, update certification processes and strengthen data privacy provisions. The Health Information Technology Advisory Committee said the coalition's recommendations would be taken into consideration in its annual report.

Full Story:
Healthcare Dive
9/18/2019

Artificial intelligence and machine learning platforms that do not include demographically representative data could produce biased results and reinforce existing clinical biases, biomedical ethics and medicine professor David Magnus said in the keynote address at the American Society for Radiation Oncology's annual meeting. In a moderated discussion after the address, machine learning and health care professor Suchi Saria said algorithms must be designed more holistically to account for biases.

9/18/2019

The fetal sides of all placentas from 25 nonsmoking women contained black carbon particles, or soot, with the highest placental levels found among those with the greatest pollution exposure during pregnancy, according to a Belgian study in Nature Communications. The researchers said more studies would be needed to show whether the particles can directly reach the fetus.

Full Story:
CNN, BBC
9/18/2019

A US judge has authorized Purdue Pharma to continue operating as it seeks bankruptcy protection and the settlement of more than 2,600 lawsuits concerning its role in the opioid epidemic. Keeping the company in business is seen as an essential part of the settlement.

Full Story:
The Associated Press
More Summaries:
Purdue Pharma
9/18/2019

A study in the Journal of Alzheimer's Disease found that older adults with amnestic mild cognitive impairment who did aerobic exercise four to five times weekly had slower hippocampal degeneration compared with those who did stretching exercises. However, researchers found similar amyloid-beta protein buildup and general brain volume between both groups, who received PET and MRI scans.

Full Story:
CNN, New Atlas
9/18/2019

Researchers found that a clinical radiomics model including cancer stage and pretreatment FDG-PET/CT-derived bone marrow, tumor and penumbra features yielded accurate prediction of adverse outcomes in patients with non-small cell lung cancer, as well as a binary score classifying those with elevated or low poor outcome risk, resulting in better prognostic accuracy, compared with a model containing cancer stage alone. The radiomic model, described in a radiology journal, "could assist clinicians in stratifying patients at a higher risk of recurrence that may benefit from more aggressive adjuvant and personalized treatment options," said researcher Sarah Mattonen.

Full Story:
Health Imaging online
9/18/2019

Researchers are studying engineered microvesicles as tiny transporters for treatments in mouse models of breast cancer, according to a study in the journal Molecular Cancer Therapeutics.

9/18/2019

As part of a new initiative called Project Orbis, the FDA, Health Canada and the Australian Therapeutic Goods Administration simultaneously approved the two-drug combination of Merck's Keytruda, or pembrolizumab, and Eisai's Lenvima, or lenvatinib, as a treatment for advanced endometrial carcinoma. The approval marks the first time the FDA has collaborated with international partners on concurrent submission and review of a cancer treatment.